(Q34186428)

31 July 2017

1 reference

title

Elderly patients at risk for coronary heart disease or stroke: selecting an ideal product for lipid lowering (English)

1 reference

31 July 2017

main subject

coronary artery disease

1 reference

Rackley CE

1

1 reference

31 July 2017

publication date

1 March 2001

1 reference

The American Journal of Geriatric Cardiology

31 July 2017

published in

1 reference

31 July 2017

volume

10

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

77-82; quiz 82-4

1 reference

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Vascular effects of statins in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Role of endothelium in ischemic coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Cardiovascular pharmacology of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Natural statins and stroke risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

The design of a prospective study of pravastatin in the elderly at risk (PROSPER)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2001.00838.X

10.1111/J.1076-7460.2001.00838.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference